Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2023, with the report dated May 02, 2023. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data as of April 30, 2023.
- Issued Share Capital: 4,312,048,912 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,068,169 Ordinary Shares.
- Total Voting Rights: 4,094,980,743.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports the static capital position as of April 30, 2023, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of share capital figures intended to assist shareholders in calculating notification thresholds under FCA rules.
Important Facts for Investors
- The total number of voting rights in GSK plc is 4,094,980,743 as of April 30, 2023.
- Shareholders should use the total voting rights figure as the denominator for determining if they are required to notify their interest or changes in interest under FCA rules.
- Notifications regarding share interests should be sent to company.secretary@gsk.com.